BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19949901)

  • 1. Antitumor effect of mSurvivinThr34→Ala in murine colon carcinoma when administered intravenously.
    Li HX; Zhao XY; Wang L; Wang YS; Kan B; Xu JR; Li J; Wen YJ; Peng XC; Chen X; Yan F; Ye B; Du XB; Zhao JM; Yi T; Chen XC; Du XX; Wei YQ; Zhao X
    Med Oncol; 2010 Dec; 27(4):1156-63. PubMed ID: 19949901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34-->Ala mutant.
    Peng XC; Yang L; Yang LP; Mao YQ; Yang HS; Liu JY; Zhang DM; Chen LJ; Wei YQ
    J Exp Clin Cancer Res; 2008 Sep; 27(1):46. PubMed ID: 18816410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A.
    Zhang L; Gao X; Men K; Wang B; Zhang S; Qiu J; Huang M; Gou M; Huang N; Qian Z; Zhao X; Wei Y
    Int J Nanomedicine; 2011; 6():2419-27. PubMed ID: 22072877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated virus-mediated survivin mutant Thr34Ala cooperates with oxaliplatin to inhibit tumor growth and angiogenesis in colon cancer.
    Xue Z; Sun PH; Zhu LM; Jiang SH; Qiao MM; Chi AL; Tu SP
    Oncol Rep; 2011 Apr; 25(4):1039-46. PubMed ID: 21279308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of doxorubicin and plasmid by a novel FGFR-mediated cationic liposome.
    Xiao W; Chen X; Yang L; Mao Y; Wei Y; Chen L
    Int J Pharm; 2010 Jun; 393(1-2):119-26. PubMed ID: 20416367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of cisplatin sensitivity in Lewis Lung carcinoma by liposome-mediated delivery of a survivin mutant.
    Yu DD; Wang CT; Shi HS; Li ZY; Pan L; Yuan QZ; Leng F; Wen Y; Chen X; Wei YQ
    J Exp Clin Cancer Res; 2010 May; 29(1):46. PubMed ID: 20462440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of survivin dominant negative mutant in a mouse model of prostate cancer.
    Pan L; Peng XC; Leng F; Yuan QZ; Shan Y; Yu DD; Li ZY; Chen X; Xiao WJ; Wen Y; Ma TT; Yang L; Mao YQ; Yang HS; Wei YQ; Wang CT
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):19-28. PubMed ID: 20217127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of lymphatic metastases by a survivin dominant-negative mutant.
    Xu GC; Zhang P; Leng F; Pan L; Li ZY; Yu DD; Shan Y; Yuan QZ; Wen Y; Mu B; Shi HS; Chen X; Wang CT
    Oncol Res; 2012; 20(12):579-87. PubMed ID: 24139416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-prostate cancer activity of Survivin-T34A mutant in vitro and in vivo].
    Pan L; Peng XC; Yuan QZ; Leng F; Yu DD; Shan Y; Li ZY; Wang CT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 May; 41(3):390-3. PubMed ID: 20629305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice.
    Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T
    Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
    Ishizaki H; Manuel ER; Song GY; Srivastava T; Sun S; Diamond DJ; Ellenhorn JD
    Cancer Immunol Immunother; 2011 Jan; 60(1):99-109. PubMed ID: 20960189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SurvivinT34A increases the therapeutic efficacy of arsenic trioxide in mouse hepatocellular carcinoma models.
    Huang A; Yue D; Liao D; Cheng L; Ma J; Wei Y; Tong A; Cheng P
    Oncol Rep; 2016 Dec; 36(6):3283-3290. PubMed ID: 27748945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced tumor radiosensitivity by a survivin dominant-negative mutant.
    Yuan QZ; Wang CT; Mao YQ; Zhang P; Shi HS; Li ZY; Pan L; Yu DD; Leng F; Chen X; Ying W; Xu JH; Li W; Wu F; Wen Y; Ma TT; Wei YQ
    Oncol Rep; 2010 Jan; 23(1):97-103. PubMed ID: 19956869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-tumor effects of recombinant adenovirus encoding survivin encapsulated in cationic liposome].
    Yang YL; Ding ZY; Li Q; Zhou H; Deng HX; Tian L; Wei YQ
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):704-7. PubMed ID: 17037732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human lung adenocarcinoma growth using survivint34a by low-dose systematic administration.
    Shan Y; Wang C; Yang L; Chen LJ; Deng HX; Yang HS; Li Z; Li Z; Pan L; Leng F; Wei Y
    J Biosci; 2010 Jun; 35(2):209-16. PubMed ID: 20689177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Caspy2 and IP-10 gene therapy significantly improves therapeutic efficacy against murine malignant neoplasm growth and metastasis.
    Zhang N; Yang Y; Cheng L; Zhang XM; Zhang S; Wang W; Liu SY; Wang SY; Wang RB; Xu WJ; Dai L; Yan N; Fan P; Dai LX; Tian HW; Liu L; Deng HX
    Hum Gene Ther; 2012 Aug; 23(8):837-46. PubMed ID: 22548488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy.
    Zhang X; Men K; Zhang Y; Zhang R; Yang L; Duan X
    Int J Nanomedicine; 2019; 14():2733-2751. PubMed ID: 31118608
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of DESI2 and endostatin gene therapy significantly improves antitumor efficacy by accumulating DNA lesions, inducing apoptosis and inhibiting angiogenesis.
    Yan H; Guo W; Li K; Tang M; Zhao X; Lei Y; Nie CL; Yuan Z
    Exp Cell Res; 2018 Oct; 371(1):50-62. PubMed ID: 30055135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant.
    Tu SP; Cui JT; Liston P; Huajiang X; Xu R; Lin MC; Zhu YB; Zou B; Ng SS; Jiang SH; Xia HH; Wong WM; Chan AO; Yuen MF; Lam SK; Kung HF; Wong BC
    Gastroenterology; 2005 Feb; 128(2):361-75. PubMed ID: 15685548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fowlpox-based survivin vaccination for malignant mesothelioma therapy.
    Bertino P; Panigada M; Soprana E; Bianchi V; Bertilaccio S; Sanvito F; Rose AH; Yang H; Gaudino G; Hoffmann PR; Siccardi A; Carbone M
    Int J Cancer; 2013 Aug; 133(3):612-23. PubMed ID: 23335100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.